C. Moskowitz

发表

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

R. Advani, P. Bierman, L. Gordon, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes

A. LaCasce, A. Zelenetz, A. Ng, 2016, Haematologica.

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

M. Shipp, P. Zinzani, P. Armand, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential Expression Patterns of c-REL Protein in Classic and Nodular Lymphocyte Predominant Hodgkin Lymphoma

A. Zelenetz, J. Teruya-Feldstein, R. Chaganti, 2004, Applied immunohistochemistry & molecular morphology : AIMM.

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

A. Zelenetz, L. Schwartz, S. Horwitz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.

A. Zelenetz, H. Schoder, C. Moskowitz, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

J. Friedberg, J. Leonard, B. Cheson, 2015 .

CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma.

M. Perales, M. Sadelain, K. Curran, 2019, Blood.

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.

A. Zelenetz, D. Correa, L. Deangelis, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).

M. Sadelain, K. Curran, R. Brentjens, 2015 .

1009 Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas

A. Zelenetz, O. O’Connor, D. Schenkein, 2003 .

Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma

H. Lazarus, S. Giralt, C. Moskowitz, 2019, Expert review of hematology.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Sonali M. Smith, A. LaCasce, J. Friedberg, 2019, Blood.

Metabolic Tumor Volume in Lymphoma: Hype or Hope?

H. Schöder, C. Moskowitz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

A. Zelenetz, S. Larson, S. Horwitz, 2016, The Journal of Nuclear Medicine.

R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.

N. Schmitz, C. Gisselbrecht, N. Mounier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

D. Northfelt, N. Bartlett, J. Drachman, 2009 .

Standard of Care Relapsed DLBCL

R. Houot, C. Moskowitz, M. Scordo, 2018, Künstliche Photosynthese.

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Nademanee, P. Stiff, V. Bachanova, 2015, The Lancet.

Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.

K. Goodman, E. Riedel, C. Moskowitz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

A. Zelenetz, H. Schoder, M. Perales, 2012, Blood.

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

R. Advani, A. Zelenetz, J. Friedberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.

H. Eich, R. Advani, A. Ng, 2018, International journal of radiation oncology, biology, physics.

Treatment of relapsed and refractory Hodgkin Lymphoma.

C. Moskowitz, B. von Tresckow, 2016, Seminars in hematology.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

A. Zelenetz, J. Friedberg, L. Constine, 2016, Blood.

Hodgkin lymphoma, version 2.2015.

R. Advani, P. Bierman, L. Gordon, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, M. Perales, S. Horwitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

A. Zelenetz, M. Perales, Zhigang Zhang, 2009, British journal of haematology.

Relapsed and Refractory Hodgkin Lymphoma

C. Moskowitz, B. Tresckow, 2017, Hodgkin Lymphoma.

Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience

N. Shukla, P. Steinherz, Zhengming Chen, 2018, Leukemia & lymphoma.

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma

O. Casasnovas, M. Hutchings, P. Borchmann, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Guideline Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma : Guidelines from the American Society for Blood and Marrow Transplantation

J. Vose, M. Perales, A. Evens, 2015 .

Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

J. Vose, M. Perales, A. Evens, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging

A. Zelenetz, J. Teruya-Feldstein, S. Nimer, 2010, British journal of haematology.

An update on the management of relapsed and primary refractory Hodgkin's disease.

C. Moskowitz, 2004, Seminars in oncology.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

A. Zelenetz, S. Horwitz, A. Younes, 2019, Blood.

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres

B. Pohlman, E. Copelan, R. Sobecks, 2011, British journal of haematology.

Adverse prognostic significance of CD20 positive Reed–Sternberg cells in classical Hodgkin's disease *

A. Zelenetz, S. Horwitz, O. O’Connor, 2004, British journal of haematology.

Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.

C. Moskowitz, M. Velez, S. Vardhana, 2018, The oncologist.

Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily.

C. Moskowitz, 2018, Blood advances.

Transplant strategies in relapsed/refractory Hodgkin lymphoma.

C. Moskowitz, G. Shah, 2018, Blood.

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.

C. Moskowitz, 2016, Hematology. American Society of Hematology. Education Program.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

A. Zelenetz, N. Shukla, M. Perales, 2015, The Lancet. Oncology.

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.

P. Zinzani, P. Armand, J. Kuruvilla, 2020, Blood advances.

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis

M. Shipp, N. Johnson, J. Radford, 2020, Leukemia & lymphoma.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087.

M. Shipp, N. Johnson, J. Radford, 2019, Blood.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

M. Shipp, P. Zinzani, P. Armand, 2017, Blood.

The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

A. Zelenetz, M. Perales, S. Devlin, 2016, British journal of haematology.

Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma.

C. Moskowitz, G. Shah, 2016, Hematology/oncology clinics of North America.

Highlights in lymphoma from the 2014 European Hematology Association Congress.

C. Moskowitz, 2014, Clinical advances in hematology & oncology : H&O.

Interim PET-CT in the management of diffuse large B-cell lymphoma.

C. Moskowitz, 2012, Hematology. American Society of Hematology. Education Program.

Reply to A. Hüttmann et al

A. Zelenetz, H. Schöder, C. Moskowitz, 2010 .

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

A. Zelenetz, D. Mould, S. Horwitz, 2007, British journal of haematology.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

N. Schmitz, G. Salles, J. Radford, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab for Aggressive Non‐Hodgkin's Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation

A. Zelenetz, J. Teruya-Feldstein, C. Moskowitz, 2002, Cancer journal.

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

A. Zelenetz, J. Glassman, J. Bertino, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy

A. Zelenetz, S. Horwitz, O. O’Connor, 2005, Leukemia & lymphoma.

Granulocyte-Colony Stimulating Factor (G-CSF) May Improve Disease Outcome in Elderly Patients with Diffuse Large Cell Lymphoma (DLCL) Treated with CHOP Chemotherapy

A. Zelenetz, J. Glassman, J. Bertino, 2000, Leukemia & lymphoma.

Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients.

A. Zelenetz, A. Dogan, B. Imber, 2021, Blood advances.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, M. Perales, M. Fleisher, 2017, Blood.

Current status of the role of PET imaging in diffuse large B-cell lymphoma.

H. Schöder, C. Moskowitz, 2015, Seminars in hematology.

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

J. Vose, A. Zelenetz, J. Winter, 2010, Clinical Cancer Research.

Consolidation therapy after autologous stem cell transplant in relapsed/refractory Hodgkin lymphoma.

C. Moskowitz, 2016, Clinical advances in hematology & oncology : H&O.

PET-adapted salvage therapy for Hodgkin's lymphoma--authors' reply.

H. Schöder, C. Moskowitz, A. Moskowitz, 2015, The Lancet. Oncology.

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, J. Vanak, C. Moskowitz, 2010, Blood.

Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma

I. Lossos, I. Reis, Feng Miao, 2021, Leukemia & lymphoma.

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

V. Seshan, A. Zelenetz, D. Mould, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase ‘2-1-2’ study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

D. Mould, S. Horwitz, F. Sirotnak, 2007 .

Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.

A. Zelenetz, M. Fleisher, S. Horwitz, 2005 .

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

G. Salles, A. Zelenetz, S. Horwitz, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Barriers to Mental Health Service Use among Hematopoietic Stem Cell Transplant Survivors

Yuelin Li, C. Rini, L. Isola, 2009, Bone Marrow Transplantation.

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

A. Nademanee, P. Stiff, V. Bachanova, 2018, Blood.

PET-Based Staging Reduces the Prognostic Impact of Early Disease Progression in Patients with Follicular Lymphoma

V. Seshan, A. Zelenetz, M. Federico, 2019, SSRN Electronic Journal.

Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma

A. Alencar, C. Moskowitz, 2019, Nature Reviews Clinical Oncology.

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

A. Zelenetz, S. Horwitz, S. Nimer, 2005 .

Psychological distress in long‐term survivors of hematopoietic stem cell transplantation

G. Winkel, W. Redd, C. Moskowitz, 2008, Psycho-oncology.

Checkpoint inhibition in lymphoma.

C. Moskowitz, G. Shah, 2018, Clinical advances in hematology & oncology : H&O.

Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma

G. Salles, A. Zelenetz, E. Drill, 2021, Haematologica.

Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.

S. Devlin, Junting Zheng, C. Moskowitz, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pre-Transplant FDG-PET Scan Lacks Prognostic Value in Chemosensitive B-Cell Non-Hodgkin Lymphoma Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation.

J. Goldberg, M. Perales, W. Cohen-Levy, 2012 .

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

A. Zelenetz, A. Iasonos, O. O’Connor, 2011, Clinical Cancer Research.

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

A. Zelenetz, J. Wright, O. O’Connor, 2009, British journal of haematology.

Patients with chemotherapy‐refractory mantle cell lymphoma experience high response rates and identical progression‐free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

J. Vose, L. Gordon, A. Zelenetz, 2009, British journal of haematology.

A multicentre phase II clinical experience with the novel aza‐epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non‐Hodgkin lymphoma and mantle cell lymphoma

A. Zelenetz, M. Stubblefield, A. Colevas, 2008, British journal of haematology.

Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of deescalation and efficacy of escalation in the international RATHL study (CRUK/07/033).

C. Moskowitz, 2015, Clinical advances in hematology & oncology : H&O.

Autologous Transplantation for Hodgkin’s Disease

S. Nimer, C. Moskowitz, 2000 .

Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.

P. Maslak, S. Nimer, C. Moskowitz, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.

A. Zelenetz, C. Moskowitz, C. Moskowitz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.

A. Zelenetz, S. Horwitz, A. Younes, 2013, Clinical advances in hematology & oncology : H&O.

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

D. Correa, L. Deangelis, A. Omuro, 2015, Blood.

Highlights in Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting and the 14th International Conference on Malignant Lymphoma.

C. Moskowitz, 2017, Clinical advances in hematology & oncology : H&O.

Highlights in lymphoma from the 12th International Conference on Malignant Lymphoma.

C. Moskowitz, 2013, Clinical advances in hematology & oncology : H&O.

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.

A. Ng, L. Specht, L. Constine, 2018, International journal of radiation oncology, biology, physics.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E Smith, Bruce D Cheson, Andreas Engert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

G. Salles, A. Zelenetz, A. Younes, 2020 .

Hodgkin lymphoma.

R. Advani, P. Bierman, L. Gordon, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Controversies in the treatment of lymphoma with autologous transplantation.

C. Moskowitz, A. Moskowitz, 2009, The oncologist.

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma.

M. Perales, S. Devlin, C. Rondon-Clavo, 2021, Blood advances.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

R. Advani, P. Bierman, L. Gordon, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Updated Efficacy and Safety Data From the AETHERA Trial of Consolidation With Brentuximab Vedotin After Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse.

P. Stiff, V. Bachanova, T. Masszi, 2016, Clinical advances in hematology & oncology : H&O.

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

A. Nademanee, P. Stiff, V. Bachanova, 2015 .

Mantle cell lymphomas.

C. Moskowitz, 2005, Clinical advances in hematology & oncology : H&O.

CD5 Negative, Cyclin D1-positive Diffuse Large B-cell Lymphoma (DLBCL) Presenting as Ruptured Spleen

J. Teruya-Feldstein, A. Gopalan, C. Moskowitz, 2009, Applied immunohistochemistry & molecular morphology : AIMM.

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

P. Stiff, V. Bachanova, T. Masszi, 2014 .

Reply to M.E. Juweid et al

A. Zelenetz, H. Schöder, C. Moskowitz, 2010 .

The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma

R. Boellaard, M. Kersten, H. D. de Vet, 2022, The Journal of Nuclear Medicine.

Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Sonali M. Smith, A. LaCasce, J. Friedberg, 2018, Blood.

Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

J. Vose, S. Mineishi, M. Horowitz, 2011 .

Phase II study of idelalisib, a selective inhibitor of PI3K d , for relapsed/refractory classical Hodgkin lymphoma

A. Younes, M. Fanale, C. Moskowitz, 2017 .

Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

A. Zelenetz, S. Horwitz, O. O’Connor, 2006 .

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

N. Schmitz, C. Gisselbrecht, N. Mounier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab and poor-risk follicular lymphoma

C. Moskowitz, 2005 .

A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.

M. Dolled-Filhart, K. Emancipator, P. Zinzani, 2014 .

A Deep Learning-Aided Automated Method for Calculating Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma

I. Lossos, Weizhao Zhao, D. Kwon, 2022, Cancers.

Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design

A. Zelenetz, A. Younes, E. Drill, 2022, Leukemia & lymphoma.

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

A. Zelenetz, J. Goldberg, S. Horwitz, 2013, Clinical lymphoma, myeloma & leukemia.

Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma

A. Zelenetz, J. Teruya-Feldstein, S. Horwitz, 2006, British journal of haematology.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

M. Shipp, N. Johnson, J. Radford, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

N. Schmitz, J. Radford, C. Gisselbrecht, 2017, Bone Marrow Transplantation.

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

N. Schmitz, G. Salles, J. Radford, 2016, Bone Marrow Transplantation.

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

A. Zelenetz, J. Teruya-Feldstein, A. Goy, 2003, Cancer.

Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.

Narasimhan P. Agaram, L. Qin, M. Arcila, 2015, European journal of cancer.

Controversies in BMT for lymphoma.

R. Gascoyne, T. Shea, C. Moskowitz, 2013, Biology of Blood and Marrow Transplantation.

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

V. Seshan, G. Salles, A. Zelenetz, 2021, Clinical Cancer Research.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

A. Zelenetz, C. Sima, J. Teruya-Feldstein, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

C. Brennan, N. Schultz, A. Viale, 2017, Cancer discovery.

Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide

A. Omuro, M. Matasar, C. Moskowitz, 2015, Leukemia & lymphoma.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

A. Zelenetz, J. Teruya-Feldstein, S. Nimer, 2004, Blood.

Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells

O. Elemento, G. Wertheim, M. Oberley, 2021, bioRxiv.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

R. Advani, J. Vose, A. LaCasce, 2018, Blood.

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

A. Zelenetz, A. Goy, C. Moskowitz, 2004, Blood.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

R. Advani, P. Bierman, L. Gordon, 2018 .

Phase II study of idelalisib, a selective inhibitor of PI3K&dgr;, for relapsed/refractory classical Hodgkin lymphoma

A. Younes, S. Mitra, M. Fanale, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.

J. Gabrilove, S. Heimfeld, S. Nimer, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

An Evidence-Based Approach to the Management of Hodgkin’s Lymphoma

C. Moskowitz, 2006 .

Stem Cell Transplantation for Aggressive Non-Hodgkin ’ s Lymphoma

C. Moskowitz, T. Kewalramani, 2001 .

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

V. Seshan, A. Zelenetz, E. Papaemmanuil, 2018, Blood Cancer Journal.

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy

L. Lekakis, C. Moskowitz, 2019, HemaSphere.

A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.

L. Deangelis, A. Omuro, S. Giralt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) followed by consolidation high-dose chemotherapy (HDC) and autologous stem-cell transplant (ASCT) for newly diagnosed primary CNS lymphoma (PCNSL).

D. Correa, L. Deangelis, A. Omuro, 2012 .

9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

P. Stiff, M. Fanale, C. Moskowitz, 2009 .

Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.

A. Rimner, Zhigang Zhang, M. Matasar, 2017, International journal of radiation oncology, biology, physics.

Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era

A. Zelenetz, Zhigang Zhang, K. Woo, 2017, British journal of haematology.

lymphoma cell transplantation for relapsed or primary refractory diffuse large B-cell Rituximab and ICE (RICE) as second-line therapy prior to autologous stem

A. Zelenetz, J. Teruya-Feldstein, S. Nimer, 2013 .

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

A. Zelenetz, A. Reiner, P. Hamlin, 2009, Bone Marrow Transplantation.

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

J. Gabrilove, J. Bertino, P. Hamlin, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary mediastinal large B‐cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999

A. Zelenetz, S. Horwitz, P. Hamlin, 2005, British journal of haematology.

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

A. Zelenetz, J. Satagopan, S. Nimer, 2003, Blood.

High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.

A. Zelenetz, S. Nimer, C. Moskowitz, 2000, Blood.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Zelenetz, D. Esseltine, M. Stubblefield, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.

J. Gabrilove, A. Ho, S. Nimer, 1997, Blood.

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

R. Advani, B. Shah, Stella K. Kim, 2015 .

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

M. Shipp, P. Zinzani, G. Martinelli, 2014 .

BCL6 and outcome in diffuse large B-cell lymphoma: a work in progress

A. Zelenetz, P. Hamlin, C. Moskowitz, 2007 .

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.

R. Advani, J. Vose, A. LaCasce, 2021, Blood.

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

R. Advani, J. Vose, A. LaCasce, 2019, Blood.

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

A. Zelenetz, A. Toure, S. Horwitz, 2019, Blood Cancer Journal.

Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.

A. Zelenetz, L. Abrey, J. Vanak, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease

A. Zelenetz, S. Nimer, C. Moskowitz, 2004, British journal of haematology.

Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma

A. Zelenetz, C. Moskowitz, A. Noy, 2001, Leukemia & lymphoma.

Central nervous system involvement in T-cell lymphoma: A single center experience

A. Zelenetz, S. Horwitz, M. Lunning, 2016, Acta oncologica.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

V. Seshan, A. Zelenetz, M. Federico, 2020, European journal of cancer.

Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation

I. Lossos, A. Alencar, J. Schatz, 2019, American journal of hematology.

Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.

N. Schmitz, C. Gisselbrecht, M. Bargetzi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.

C. Moskowitz, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

A. Olshen, A. Zelenetz, J. Teruya-Feldstein, 2005, Blood.

Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.

A. Zelenetz, M. Gönen, H. Schöder, 2015, Radiology.

Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma.

A. Zelenetz, H. Schoder, S. Devlin, 2015, Blood.

Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.

J. Vose, R. Fisher, M. Horowitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood Cancer Journal.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.

I. Lossos, M. Czuczman, T. Shea, 2013, Blood.

A roadmap for clinical trial design in marginal zone lymphoma

I. Lossos, A. Zelenetz, T. Habermann, 2022, American journal of hematology.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

J. Friedberg, J. Leonard, B. Cheson, 2018, Blood.

PET imaging for response assessment in lymphoma: potential and limitations.

H. Schöder, C. Moskowitz, 2008, Radiologic clinics of North America.

Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.

A. Zelenetz, P. Hamlin, A. Ni, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma

H. Lazarus, S. Giralt, C. Moskowitz, 2019, Expert review of hematology.

Stem Cell Factor

G. Demetri, G. Tricot, C. Begley, 2000 .

A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.

A. Zelenetz, J. Goldberg, M. Perales, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.

A. Alencar, C. Moskowitz, 2021, Journal of Clinical Oncology.

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma

A. Zelenetz, A. Younes, E. Drill, 2019, Haematologica.

Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B‐cell lymphoma in the rituximab era

A. Zelenetz, M. Lunning, J. Migliacci, 2015, British journal of haematology.

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

R. Advani, B. Shah, P. Hamlin, 2014 .

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Effectiveness of partner social support predicts enduring psychological distress after hematopoietic stem cell transplantation.

C. Schetter, C. Rini, L. Isola, 2011, Journal of consulting and clinical psychology.

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

A. Zelenetz, J. Wright, O. O’Connor, 2004, The Journal of the National Comprehensive Cancer Network.

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

A. Zelenetz, J. Goldberg, M. Perales, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

M. Shipp, N. Johnson, J. Radford, 2016 .

Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation

D. Goldman, Zhigang Zhang, M. Matasar, 2015, British journal of haematology.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

A. Zelenetz, M. Voss, A. Chen, 2017, Clinical Cancer Research.

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

C. Bennett, D. Raisch, O. Sartor, 2014, Cancer.

False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.

A. Zelenetz, M. Gönen, G. Ulaner, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

A. Zelenetz, H. Schoder, S. Devlin, 2018, Blood.

High Dose Chemoradiotherapy and ASCT May Overcome the Prognostic Importance of Biologic Markers in Relapsed/Refractory Hodgkin Lymphoma

J. Teruya-Feldstein, R. Saxena, D. Persky, 2010, Applied immunohistochemistry & molecular morphology : AIMM.

Upfront transplantation for poor-risk aggressive non-hodgkin lymphoma and hodgkin’s disease: Who benefits?

C. Moskowitz, T. Kewalramani, 2001, Current oncology reports.

Association of thyroid disease with acute leukemia

J. Dutcher, C. Moskowitz, P. Wiernik, 1992, American journal of hematology.

Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma.

J. Teruya-Feldstein, M. Arcila, C. Moskowitz, 2013, Leukemia research.

Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform

A. Zelenetz, P. Stephens, R. Yelensky, 2013 .

INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

J. Vose, A. LaCasce, S. Ansell, 2017 .

Defining Progression Free Survival After Multiple Lines of Therapy and Impact of Dynamic Changes in FLIPI for Multiply Relapsed Follicular Lymphoma in the Rituximab Era Treated at Memorial Sloan Kettering Cancer Center (MSKCC)

V. Seshan, A. Zelenetz, S. Horwitz, 2017 .

PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

M. Sadelain, A. Younes, R. Furman, 2019, Hematological Oncology.

Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen

A. Zelenetz, H. Schöder, A. Mauguen, 2022, The Journal of Nuclear Medicine.

Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue.

A. Zelenetz, S. Horwitz, A. Younes, 2021, Blood advances.

Diffuse large B cell lymphoma: how can we cure more patients in 2012?

C. Moskowitz, 2012, Best practice & research. Clinical haematology.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma

P. Zinzani, K. Ardeshna, F. Morschhauser, 2019, Leukemia & lymphoma.

PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker Assessment

M. Shipp, P. Zinzani, P. Armand, 2015 .

Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma

A. Zelenetz, P. Hamlin, C. Moskowitz, 2010 .

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

D. Northfelt, N. Bartlett, A. Lobuglio, 2013, Leukemia & lymphoma.

Hodgkin Lymphoma Version 1 . 2017 Clinical Practice Guidelines in Oncology

R. Advani, P. Bierman, L. Gordon, 2017 .

The role of hematopoietic stem cell transplantation in Hodgkin lymphoma.

J. Sweetenham, C. Moskowitz, 2009, Cancer treatment and research.

TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin.

M. Fleisher, H. Schöder, Zhigang Zhang, 2015, Clinical advances in hematology & oncology : H&O.

Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy

C. Moskowitz, 2002, Cancer Chemotherapy and Pharmacology.

Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation.

C. Rini, G. Winkel, Catalina R Lawsin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

R. Bociek, R. Gascoyne, L. Gordon, 2012 .

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

M. Shipp, N. Johnson, J. Radford, 2021, Blood.

Construct validity of the posttraumatic stress disorder checklist in cancer survivors: analyses based on two samples.

T. Ashman, B. Morasco, G. Winkel, 2004, Psychological assessment.

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

M. Shipp, P. Zinzani, P. Armand, 2016 .

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

A. Zelenetz, P. Mclaughlin, L. Fayad, 2010 .

toxicities and long term survival after autologous hematopoietic stem cell transplantation for older patients with relapsed refractory hodgkin lymphoma

S. Devlin, P. Hamlin, S. Giralt, 2019 .

Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.

C. Moskowitz, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The Role of Cytotoxic and Regulatory T cells in Relapsed/Refractory Hodgkin Lymphoma

J. Teruya-Feldstein, D. Persky, C. Moskowitz, 2010, Applied immunohistochemistry & molecular morphology : AIMM.

Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting

A. Zelenetz, P. Goyal, S. Horwitz, 2023, Cancers.

PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY

M. Shipp, J. Radford, P. Zinzani, 2017 .

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

A. Zelenetz, A. Toure, S. Horwitz, 2019, Blood Cancer Journal.

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

M. Shipp, N. Johnson, J. Radford, 2018, Blood.

Rituximab, bendamustine and cytarabine (RBAC500) as induction therapy in elderly patients with mantle cell lymphoma: a phase 2 study from the Fondazione Italiana Linfomi.

C. Moskowitz, 2015, Clinical advances in hematology & oncology : H&O.

PREDICTIVE VALUE OF QUANTITATIVE 18 F‐FDG‐PET‐CT RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

R. Boellaard, M. Kersten, O. Hoekstra, 2021, Hematological Oncology.

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

A. Nademanee, J. Radford, S. Ramsey, 2016, British journal of haematology.

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma

R. Advani, R. Bouabdallah, H. Tilly, 2015, Leukemia & lymphoma.

Disseminated mantle-cell lymphoma presenting as a petechial maculopapular eruption.

C. Querfeld, T. Hollmann, Sarah I Jawed, 2014, JAMA dermatology.

Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.

N. Schmitz, S. Montoto, C. Gisselbrecht, 2009 .

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

J. Vose, A. Zelenetz, J. Winter, 2004 .

Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

A. Zelenetz, S. Horwitz, A. Intlekofer, 2016 .

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

R. Advani, J. Vose, A. LaCasce, 2016 .

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

V. Seshan, A. Zelenetz, E. Papaemmanuil, 2018, Blood Cancer Journal.

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

I. Lossos, V. Seshan, A. Zelenetz, 2020 .

Managing Risk in Hodgkin Lymphoma.

J. Armitage, J. Sweetenham, C. Moskowitz, 2015, Clinical advances in hematology & oncology : H&O.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma

C. Brennan, N. Schultz, D. Louis, 2017, Neuro-oncology.

Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.

M. Shipp, N. Johnson, J. Radford, 2016 .

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

P. Stiff, T. Masszi, J. Walewski, 2014 .

Quantitative PET-based biomarkers in lymphoma: getting ready for primetime

C. Moskowitz, R. Kuker, J. Alderuccio, 2023, Nature Reviews Clinical Oncology.

Greater Total Dose and Duration of Treatment with Bortezomib Are Associated with Higher Incidence of Chalazion and Other Ocular Side Effects

A. Zelenetz, R. Motzer, N. Shukla, 2014 .

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

A. Zelenetz, A. Younes, H. Schöder, 2018 .

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

N. Schmitz, P. Gaulard, C. Gisselbrecht, 2007 .

A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma.

A. Zelenetz, J. Leonard, S. Horwitz, 2015 .

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

A. Zelenetz, S. Horwitz, A. Intlekofer, 2020 .

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Chad A. LaGrange, Geoffrey E. Wile, R. Advani, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma

A. Zelenetz, J. Teruya-Feldstein, C. Hedvat, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.

A. Zelenetz, S. Nimer, P. Hamlin, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma.

M. Shipp, N. Johnson, J. Radford, 2023, Blood.

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

J. Friedberg, J. Leonard, M. Shipp, 2023, Hematological Oncology.

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

R. Advani, A. Zelenetz, J. Friedberg, 2022, Blood.

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma

J. Radford, D. Cutter, S. Barrington, 2022, HemaSphere.

461 POSTER Early phase experience with pralatrexate (10-propargy l-10-deazaaminopterin [PRX]), a novel antifolate with high afnity forthe reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies

A. Zelenetz, D. Mould, S. Horwitz, 2006 .

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

A. Zelenetz, S. Nimer, J. Qin, 2003, Bone Marrow Transplantation.

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

A. Zelenetz, J. Bertino, J. Bertino, 2001, Blood.

Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome

A. Zelenetz, J. Teruya-Feldstein, C. Moskowitz, 2008 .

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

A. Zelenetz, A. Dogan, A. Younes, 2023, Haematologica.

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

V. Seshan, A. Zelenetz, A. Dogan, 2023, Leukemia and Lymphoma.

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

I. Lossos, M. Czuczman, T. Shea, 2013 .

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

M. Shipp, P. Zinzani, P. Armand, 2016 .

Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.

M. Perales, S. Devlin, S. Giralt, 2023, Leukemia & lymphoma.

Effectiveness of partner social support predicts enduring psychological distress after hematopoietic stem cell transplantation.

C. Schetter, C. Rini, L. Isola, 2011, Journal of consulting and clinical psychology.

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

M. Shipp, N. Johnson, J. Radford, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Scott E. Smith, J. Connors, S. de Vos, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).

R. Advani, B. Shah, A. Forero-Torres, 2014 .

Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment.

A. Zelenetz, S. Horwitz, P. Hamlin, 2006 .

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

J. Vose, A. Zelenetz, J. Winter, 2010, Clinical Cancer Research.

Prognostic Significance of Positron Emission Tomography (FDG-PET) at Baseline and After 4 Cycles of R-CHOP in 75 Patients with Mantle Cell Lymphoma Treated with Intensive Chemotherapy and Autologous Stem Cell Rescue.

A. Zelenetz, C. Hedvat, C. Moskowitz, 2009 .

The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

A. Zelenetz, A. Reiner, P. Hamlin, 2009, Bone Marrow Transplantation.

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.

A. Zelenetz, M. Liedtke, P. Hamlin, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Positron-emission tomography e based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

V. Seshan, A. Zelenetz, M. Federico, 2020 .

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.

A. Ng, L. Specht, L. Constine, 2018, International journal of radiation oncology, biology, physics.

The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma

A. Zelenetz, J. Glassman, J. Bertino, 1999, Bone Marrow Transplantation.

Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma.

A. Zelenetz, C. Moskowitz, Basciano A. Basciano, 2009 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma

J. Zijlstra, H. Schöder, C. Moskowitz, 2023, Blood advances.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

R. Advani, P. Bierman, L. Gordon, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)

I. Lossos, M. Czuczman, T. Shea, 2011 .

Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

A. Zelenetz, S. Larson, S. Horwitz, 2016, The Journal of Nuclear Medicine.